Welcome to the new scientist and researcher reference section. Your one-stop shop for the essential resources you need to advance your career.
The SNMMI Future Leaders Academy training focuses on setting a clear plan for increasing leadership abilities by developing the necessary skills and organizational expertise to enhance performance and ultimately evolve into a leader both within the nuclear medicine and molecular imaging community and the society.
SNMMI educational programs are designed to meet the professional development needs of scientists involved in nuclear medicine and molecular imaging endeavors.
The most up-to-date and comprehensive source for nuclear medicine coding and reimbursement information on the web. Please note that ALL information and materials within the SNMMI Coding Corner are direct products of the SNMMI Coding and Reimbursement Working Group.
For Hospitals (APCs, IPPS) Find general coding and reimbursement information for hospitals.
For Private Practices (RBRVS) Find general coding and reimbursement information for professionals in private practices.
Coding and Reimbursement Q&A This easy to use feature contains over 100 questions and answers related to topics such as cardiac, endocrine, neurology, nuclear medicine-related drugs, oncology, PET, PET/CT, radiopharmaceuticals, and more!
In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.
SNMMI has a large body of knowledge in dose optimization that is continually growing and developing. The dose optimization website presents a wide variety of resources, including SNMMI journal articles, educational offerings, media-related information, links to useful websites and more.
The goal of the SNMMI Best Practices in Preclinical Imaging Initiative is to provide guidelines based on the community experience in designing and conducting preclinical imaging experiments.
Available Resources Include:
SNMMI's Center for Molecular Imaging Innovation and Translation is an organizational component within the SNMMI that is dedicated to all aspects of molecular imaging in the detection and management of disease. The center is currently facilitating initiatives to bring molecular imaging discoveries from the lab to the patient and to advance "personalized" medicine.
The Clinical Trials Network’s mission is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new agents to regulatory approval. Click here to learn more about the CTN’s Oncology and Neurology Scanner Validation programs, ongoing efforts to harmonize reconstruction parameters in oncology clinical trials, and other services that CTN offers to help scientists advance their research.
The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some guidelines were formally adopted by SNMMI in collaboration with other professional organizations.
A new study reports that a targeted molecular contrast agent can be used successfully to cause lung adenocarcinomas to fluoresce during pulmonary surgery.
(MI: Making a Difference)
Additional information is now available regarding the ABR/ABNM Task Force proposal: an ABNM response to the June 4 SNMMI letter and answers to frequently asked questions. Please provide your input today!
Results from the randomized intergroup European Organisation for Research and Treatment of Cancer, Lymphoma Study Association and Fondazione Italiana Linfomi H10 trial have demonstrated that early FDG-PET adapted treatment improves outcomes of early FDG-PET-positive patients with stage I/II Hodgkin’s lymphoma (HL).
(MI: Making a Difference)
Overdiagnosis is commonly discussed in areas like breast imaging, where screening is widely conducted and media interest is high. While it’s under the radar for other diseases, it’s a big enough topic in the medical world to warrant a dedicated issue in Academic Radiology.
(MI: Making a Difference)
Register today for the SNMMI 2015 Annual Meeting, June 6-10, in Baltimore, Maryland. This year's meeting features more than 150 scientific and CE sessions, covering the latest advances in the profession, including:
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the National Cancer Institute (NCI) held a joint workshop—NCI-SNMMI Workshop on Targeted Radionuclide Therapy—on October 24-25, 2014, at the National Institutes of Health (NIH) in Bethesda, Md.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.